SGBCC 2023 – thank you!

We would like to express our sincere gratitude for your valuable contribution to the 18th St.Gallen International Breast Cancer Conference 2023. It brings us great pleasure to see so many delegates come together every two years to learn about the latest developments in the treatment of individuals with early breast cancer, and your presence and contribution played an integral part in making the conference a success.

As per tradition, the conference concluded with an update on the widely acknowledged „St.Gallen International Consensus on the Primary Treatment of Individuals with Early Breast Cancer,“ which will be published just a few months after the conference.

Once again, we would like to thank you for your participation and contribution to this important event, and we hope to see you again in 2025!

Save the date!

The next St. Gallen International Breast Cancer Conference will take place from 12 – 15 March 2025 in Vienna. We cordially invite you to mark this date in your agenda today. Don’t miss any news and sign up for our newsletter or join us on social media to stay informed. We look forward to welcoming you at SGBCC 2025!


facebook linkedin twitter


Your SGBCC 2023 Organising Team

St.Gallen Oncology Conferences
Rorschacherstrasse 150, 9006 St.Gallen/Switzerland

conference programme


Understanding breast cancer complexity to improve patients outcomes


scientific programme quick-links

> Wednesday, 15 March 2023

> Thursday, 16 March 2023

> Friday, 17 March 2023

> Saturday, 18 March 2023


> Wednesday, 15 March 2023


13.00 - 14.00

Opening Ceremony: Welcome, Awards and Award Lectures

Chairs: Michael Gnant (Austria), Beat Thürlimann (Switzerland), Walter Weber (Switzerland)

15 min. per lecture

St.Gallen Breast Cancer Award 2023

Chairs: Beat Thürlimann (Switzerland), Walter Weber (Switzerland)

The St.Gallen Breast Cancer Award Lecture 2023:
The Saga of Theragnostic Biomarkers of Breast Cancer (Giuseppe Viale, Italy)


ESO Umberto Veronesi Memorial Award 2023

Chair: Alexandru Eniu (ESO)

The ESO Umberto Veronesi Memorial Award Lecture 2023:
A global approach to breast cancer management (Benjamin Anderson, WHO)

14.00 - 14.15

Short break

14.15 - 14.20

Best Poster Awards 2023

Chair: Beat Thürlimann (Switzerland)

14.20 - 15.30

Session 1: News in breast cancer care since SGBCC 2021

Chairs: Beat Thürlimann (Switzerland), Tanja Spanic (Slovenia)

15 min. per lecture
  • Surgery of patients with early breast cancer: Quo vadis? (Walter Weber, Switzerland)
  • Access to evidence based radiation therapy for patients with early breast cancer (Philip Poortmans, Belgium)
  • What’s new in systemic treatment of patients with early breast cancer (Roisin Connolly, Ireland)
  • Translational research priorities for patients with early breast cancer (Fabrice André, France)
  • Hot topics in survivorship, patient reported outcomes, and Quality of Life (Ann Partridge, USA)
15.30 - 16.00

Coffee break

15.30 - 16.15

SGBCC Academy

The St.Gallen-Vienna Breast Cancer Care Educationals for Professionals around the world. 

Chair: Emiel Rutgers (Netherlands)
Co-Chair: Sara Brucker (Germany)
Discussants: Stefan Aebi (Switzerland), Meteb Al-Foheidi (KSA), Zefei Jiang (China), Toru Watanabe (Japan)

16.00 - 17.30

Interactive Session I: How to avoid unnecessary mastectomies – a global discussion

Chairs: Monica Morrow (USA), Walter Weber (Switzerland)
Panelists: Meteb Al-Foheidi (KSA), Denisse Bretel (Peru), Jana de Boniface (Sweden), Fatima Cardoso (Portugal), Heba Gamal (Egypt), Eun-Sook Lee (Korea), Lori Pierce (USA), Zhiming Shao (China), Tanja Spanic (Slovenia), Masakazu Toi (Japan)

17.30 - 18.30

Welcome Apéro at the Austria Center Vienna


> back to top

> Thursday, 16 March 2023
09.00 - 10.00

Session 2: Genomics, Transcriptomics, ctDNA for disease monitoring and risk stratification

Chairs: Fabrice André (France), Meredith Regan (USA)

15 min. per lecture
  • ctDNA dynamics for early assessment of recurrence risk (Nicholas Turner, UK)
  • Molecular imaging in breast cancer (Michel van Kruchten, Netherlands)
  • Multi-omic machine learning prediction of treatment response (Carlos Caldas, UK)
  • How to assess clinical utility and clinical validity of biomarkers in clinical trials? (Meredith Regan, USA)
10.00 - 11.00

Session 3: Immunology in early breast cancer

Chairs: Sherene Loi (Australia), Aleix Prat (Spain)

15 min. per lecture
  • Understanding the anti-cancer immune response: Innate and adaptive responses to breast cancer cells (Sherene Loi, Australia)
  • Tumor microenvironment in early breast cancer (Carsten Denkert, Germany)
  • Multiplexed analysis and spatial histology to predict response (Marleen Kok, Netherlands)
  • The future of breast cancer immunotherapy (PD, PDL, vaccines) (Giuseppe Curigliano, Italy)
11.00 - 13.00

Lunch break

12.45 - 13.30

Special lecture I and panel discussion

Chair: Michael Gnant (Austria)
Panelists: David Cameron (UK), Heba Gamal (Egypt), Chiun-Sheng Huang (Taiwan)

Special lecture I
The future of innovation: Why are we conducting clinical trials in countries that are unlikely to be able to afford innovative drugs? (Sara Tolaney, USA)


13.30 - 14.30

Session 4: Hereditary Breast Cancer

Chairs: Lisa Carey (USA), Suzette Delaloge (France)

15 min. per lecture
  • Imaging, screening & surveillance for individuals with increased hereditary breast cancer risk (Suzette Delaloge, France)
  • Local treatment in patients with high risk hereditary breast cancer (Maria Joao Cardoso, Portugal)
  • Management of patients harboring medium penetrance genes (Christian Singer, Austria)
  • Adjuvant systemic therapy for patients with germline BRCA1/2 mutations (Andrew Tutt, UK)
14.30 - 15.30

Session 5: The future treatment landscape in the adjuvant setting

Chairs: Sibylle Loibl (Germany), Martine Piccart (Belgium)

15 min. per lecture
  • Post-neoadjuvant options in triple negative disease: PARPi, capecitabine, checkpoint inhibitors (Javier Cortes, Spain)
  • Risk assessment in ER positive disease: Who should receive CDK 4-6 inhibitors? (Angela De Michele, USA)
  • What’s next? Antibody drug conjugates for breast cancer therapy (Cristina Saura, Spain)
  • Integrating new oral SERDs in the adjuvant treatment (David Cameron, UK)
15.30 - 16.00

Coffee break

15.30 - 16.15

SGBCC Academy

The St.Gallen-Vienna Breast Cancer Care Educationals for Professionals around the world. 

Chair: Fatima Cardoso (Portugal)
Co-Chair: Carlos Barrios (Brazil)
Discussants: Jonas Bergh (Sweden)

16.00 - 16.45

Debate I: Early breast cancer: do we need chemotherapy in low genomic/high clinical risk (ER+/HER2-)?

Chairs: Giuseppe Curigliano (Italy), Michael Gnant (Austria)
Debaters: Lisa Carey (USA), Nadia Harbeck (Germany)

16.45 - 17.30

Interactive Session II: Too big, too small? Too low, too high? Adjuvant choices when stage and biology do not align.

Chairs: Harold Burstein (USA), Prudence Francis (Australia)
Panelists: Charlotte Coles (UK), Eun-Sook Lee (Korea), Frederique Penault-Llorca (France), Martine Piccart (Belgium), Cristina Saura (Spain), Andrew Tutt (UK)

What to do in discordant scenarios? Small tumors with high biological risk? (Case studies)


> back to top

> Friday, 17 March 2023
09.00 - 10.00

Session 6: Tailoring breast surgery and radiotherapy

Chairs: Jana de Boniface (Sweden), Lori Pierce (USA)

15 min. per lecture
  • Patient selection, dose and fractionation for external beam radiotherapy in patients with early breast cancer (Charlotte Coles, UK)
  • Benefits and risks of oncoplastic breast-conserving surgery (Marie-Jeanne Vrancken Peeters, Netherlands)
  • Breast surgery after neoadjuvant therapy (Andrea V. Barrio, USA)
  • Breast surgery for local recurrence (Isabel Rubio, Spain)
10.00 - 11.00

Session 7: Controversies in the treatment of the axilla

Chairs: Philip Poortmans (Belgium), Zhiming Shao (China)

15 min. per lecture
  • Omission of surgical staging of the axilla (Oreste Gentilini, Italy)
  • Axillary surgery in the adjuvant setting (Jana de Boniface, Sweden)
  • Limited axillary surgery concepts to determine nodal pathologic complete response (Jörg Heil, Germany)
  • De-escalation of axillary radiotherapy – the time has come! (Icro Meattini, Italy)
11.00 - 13.00

Lunch break

11.00 - 11.30

Best Poster Presentations

Chair: Beat Thürlimann (Switzerland)

13.00 - 13.45

Debate II: Axillary dissection versus axillary radiation for residual nodal disease after neoadjuvant systemic therapy

Chairs: Michal Gnant (Austria), Philip Poortmans (Belgium)
Debaters: Orit Kaidar-Person (Israel), Monica Morrow (USA) 

13.45 - 14.30

Interactive Session III: Controversies and uncertainties in axillary management

Chairs: Walter Weber (Switzerland), Bahadir Gulluoglu (Turkey)
Panelists: Jana de Boniface (Sweden), Oreste Gentilini (Italy), Orit Kaidar-Person (Israel), Eun-Sook Lee (Korea),  Monica Morrow (USA), Philip Poortmans (Belgium), Isabel Rubio (Spain), Marie-Jeanne Vrancken Peeters (Netherlands)

14.30 - 14.45

Short break

14.30 - 15.15

SGBCC Academy

The St.Gallen-Vienna Breast Cancer Care Educationals for Professionals around the world. 

Chair: Elzbieta Senkus-Konefka (Poland)
Co-Chair: Gerd Fastner (Spain)
Discussant Chiun-Sheng Huang (Taiwan)

14.45 - 15.45

Session 8: Optimizing treatment in patients with HER2-positive breast cancer

Chairs: Hope S. Rugo (USA), Masakazu Toi (Japan)

15 min. per lecture
  • Assessing HER2 heterogeneity (Frederique Penault-Llorca, France)
  • Current adjuvant and neoadjuvant approaches (Nadia Harbeck, Germany)
  • Emerging new treatments in HER2 positive breast cancer (Martine Piccart, Belgium)
  • ER positive vs ER negative: tackling diversity in HER2 positive breast cancer (Aleix Prat, Spain)
15.45 - 16.45

Session 9: Optimizing treatment in patients with triple negative breast cancer

Chairs: Lisa Carey (USA), Zefei Jiang (China)

15 min. per lecture
  • Optimal neoadjuvant and adjuvant therapy for patients with early triple negative breast cancer (Hope S. Rugo, USA)
  • Optimal systemic therapy for residual disease in TNBC (Sibylle Loibl, Germany)
  • Tackling triple negative histological subtypes in early breast cancer (Jorge Reis Filho, USA)
  • Can we de-escalate immunotherapy and chemotherapy in TNBC? (Hervè Bonnefoi, France)
16.45 - 17.30

Debate III: If you achieve pCR after neoadjuvant, do you need adjuvant therapy?

Chairs: Giuseppe Curigliano (Italy), Sherene Loi (Australia),
Debaters: Sibylle Loibl (Germany), Steven Chia (Canada)

17.30 - 17.45

Short break


> back to top


> Saturday, 18 March 2023
09.00 - 10.00

Session 10: Global Prespective on breast cancer treatment

Chairs: Carlos Barrios (Brazil), Binghe Xu (China)

15 min. per lecture
  • Breast cancer treatment and research from a global perspective (Benjamin Anderson, World Health Organization)
  • Perspective from Asia (Binghe Xu, China)
  • Perspective from Africa (Heba Gamal, Egypt)
  • Perspective from Latin America (Denisse Bretel, Peru)
10.00 - 11.00

Session 11: Optimizing treatment in patients with HR positive breast cancer

Chairs: Stefan Aebi (Switzerland)

15 min. per lecture
  • What to do when there are many options? Integrating Olaparib in BRCA-associated ER positive tumors (Sara Brucker, Germany)
  • Pre-menopausal: Who needs chemotherapy in the (neo)adjuvant setting? (Prudence Francis, Australia)
  • Can we omit adjuvant endocrine therapy? (Fatima Cardoso, Portugal)
  • Duration of endocrine therapy in early breast cancer (Jens Huober, Switzerland)
11.00 - 11.15

Short break

11.15 - 11.45

Debate IV: Surgery of the primary for stage IV disease

Chairs: William Gradishar (USA), Bahadir Gulluoglu (Turkey)

Presenting data: William Gradishar (USA)
Debaters: Rajendra Badwe (India), Florian Fitzal (Austria)

12.00 - 12.30

Lunch break

12.30 - 14.30

St.Gallen International Consensus Session I

St.Gallen International Consensus Session on the primary treatment of patients with breast cancer 2023
Seeking consensus on evidence and opinions

Moderator and Scientific Secretary: Harold Burstein (USA), Giuseppe Curigliano (Italy)

14.30 - 14.45

Short break

14.45 - 16.45

St.Gallen International Consensus Session II

St.Gallen International Consensus Session on the primary treatment of patients with breast cancer 2023
Seeking consensus on evidence and opinions

Moderator and Scientific Secretary: Harold Burstein (USA), Giuseppe Curigliano (Italy)

16.45 - 17.00





> back to top

St.Gallen International Consensus on the primary treatment of individuals with breast cancer


As per tradition, the SGBCC 2023 concluded with an update on the widely acknowledged „St. Gallen International Consensus on the Primary Treatment of Individuals with Early Breast Cancer.“ 

The list of the St.Gallen International Breast Cancer Consensus Panel 2023 can be found here.


Publication 2023

The St.Gallen Consensus and its related core issues will be published just a few months after the conference.


Publication 2021

Customizing local and systemic therapies for women with early breast cancer: The St.Gallen International Consensus Guidelines for treatment of early breast cancer 2021.

H.J. Burstein, G. Curigliano, B. Thürlimann, W.P. Weber, P. Poortmans, M. Regan, H.J. Senn, E.P. Winer, M. Gnant and Panelists of the St.Gallen Consensus Conference.


Publication 2019:

Estimating the benefits of therapy for early-stage breast cancer: read the St.Gallen International Consensus Guidelines for the Primary therapy of early breast cancer 2019 here.






Meet our chairs:

Conference co-chairs
Univ. Prof. Dr. Michael Gnant, Medical University of Vienna / Austria
Prof. Dr. med. Beat Thürlimann, Breast Centre, Kantonsspital St.Gallen / Switzerland
Prof. Dr. Walter Weber, University Hospital Basel / Switzerland

Photo: SGBCC 2023 Opening Ceremony. From left to right: W. Weber, M. Gnant, B. Thürlimann

Scientific Programme-Planning Committee
Harold Burstein, Boston, USA
Giuseppe Curigliano, Milano/Italy
Michael Gnant, Vienna/Austria
Sibylle Loibl, Neu-Isenburg/Germany
Philip Poortmans, Antwerp/Belgium
Meredith Regan, Boston, USA
Hans-Jörg Senn (✝), St.Gallen/Switzerland
Beat Thürlimann, St.Gallen/Switzerland
Walter Weber, Basel/Switzerland
Eric Winer, New Haven, USA


Conference founder and honorary chair
Prof. Dr. med. Hans-Joerg Senn (* 28 March 1934, ✝ 13 January 2023), Foundation St.Gallen Oncology Conferences (SONK), St.Gallen / Switzerland

faculty members


Conflict of Interest Statements

All faculty members of the scientific programme have submitted a conflict of interest statement.
The summary of all statements is available here.


AebiStephanSwitzerlandLuzerner Kantonsspital, Lucerne Cantonal Hospital
Al-FoheidiMetebKSAPrincess Noorah Oncology Center, National Guard Health Affairs
AndréFabriceFranceGustave Roussy
AnikuskoMikolaUkraineKyiv City Clinical Oncology Center
BadweRajendraIndiaDr. E. Borges Marg, Parel, Tata Memorial Centre
BarrioAndrea V.USAMemorial Sloan Kettering Cancer Center
BarriosCarlosBrazilLACOG – Latin American Cooperative Oncology Group, Lacog – Oncoclínicas Group
BerghJonasSwedenKarolinska Institutet and University Hospital
BonnefoiHervéFranceInstitut Bergonie Unicancer
Bretel MoralesDenissePeruGECOPERU – Medical Direction, Gecoperu
BruckerSaraGermanyTuebingen University Women’s Hospital
BursteinHarold J.USADana-Farber Cancer Institute
CaldasCarlosUKCancer Research UK Cambridge Institute, University Of Cambrige
CameronDavidUKEdinburgh Cancer Research, The University of Edinburgh, The University Of Edinburgh
CardosoFatimaPortugalChampalimaud Cancer Center
CardosoMaria JoaoPortugalChampalimaud Foundation Breast Unit
CareyLisaUSALineberger Comprehensive Cancer Center
ChiaStevenCanadaBC Cancer, Vancouver Cancer Centre, BC Cancer – Vancouver Centre
ColesCharlotteUKUniversity of Cambridge
ConnollyRoisinIrelandCancer Research at UCC and Cork University Hospital
CuriglianoGiuseppeItalyIstituto Europeo di Oncologia, IRCCS
de BonifaceJanaSwedenCapio St. Göran’s Hospital, Capio St. Göran’s Hospital And Karolinska Institutet
DelalogeSuzetteFranceGustave Roussy
DeMicheleAngelaUSAUniversity of Pennsylvania
DenkertCarstenGermanyUniversitätsklinikum Griessen und Marburg, Philipps-University Marburg
FastnerGerdAustriaDepartment of Radiotherapy and Radio-Oncology, Paracelsus Medical University, University Hospital Salzburg
FitzalFlorianAustriaMedical University of Vienna, Medical University Vienna
FrancisPrudenceAustraliaPeter MacCallum Cancer Centre, De, Peter MacCallum Cancer Centre
GamalHebaEgyptNational Cancer Institute, Cairo University
GentiliniOresteItalyS.Raffaele University and Research Hospital, San Raffaele University and Research Hospital
GnantMichaelAustriaMedical University Of Vienna – ABCSG
GradisharWilliamUSA / NCCNNorthwestern University Feinberg School of Medicine, Nccn/northwestern University
GulluogluBahadirTurkeyMarmara Universiy of Medicine, Marmara University School Of Medicine
HarbeckNadiaGermanyHead of Breast Center, Oncological Therapy and Breast Clinical Trials Unit, University of Munich
HeilJörgGermanyBreast Unit Heidelberg
HuangChiun-Sheng HuangTaiwanNational Taiwan University Hospital
HuoberJensSwitzerlandCantonal Hospital St.Gallen, Kantonsspital St.Gallen, Brustzentrum
JiangZefeiChinaFifth Medical Center of Chinese PLA General Hospital Beijing
Kaidar-PersonOritIsraelSheba Tel Hashomer, Oncology Institute, Sheba Medical Center
KokMarleenNetherlandsnetherlands cancer institute, Netherlands Cancer Institute
LeeEun-SookKoreaNational Cancer Center
LoiShereneAustraliaPeter MacCallum Cancer Centre, Peter MacCallum Cancer Centre
LoiblSibylleGermanyGBG Forschungs GmbH, Gbg Forschungs Gmbh
MeattiniIcroItalyUniversity of Florence, University Of Florence
MorrowMonicaUSAMemorial Sloan Kettering Cancer Center
PartridgeAnnUSADana Farber Cancer Institut
Penault-LlorcaFrederiqueFranceCentre Jean Perrin, centre Jean Perrin UNICANCER
PiccartMartineBelgiumInstitut Jules Bordet, Institut Jules Bordet
PierceLoriUSAUniversity of Michigan/, University Of Michigan
PoortmansPhilipBelgiumIridium Netwerk & University Of Antwerp
PratAleixSpainAugust Pi i Sunyer Biomedical Research Institute
ReganMeredithUSADana-Farber Cancer Institute,, Dana-farber Cancer Institute
Reis-FilhoJorgeUSAMemorial Sloan Kettering Cancer Center,, Memorial Sloan Kettering Cancer Center
RubioIsabelSpainClinica Universidad de Navarra, Clinica Universidad De Navarra
RugoHopeUSAniversity of California Comprehensive Cancer Center, Department of Medicine, Ucsf Helen Diller Family Comprehensive Cancer Center
RutgersEmielNetherlandsNetherlands Cancer Institute/Dept. of Surgery
SauraCristinaSpainVall d’Hebron University Hospital/ Vall D’Hebron Institute of Oncology (VHIO), Vall D’hebrón University Hospital
SenkusElzbietaPolandDepartment of Oncology and Radiotherapy, Medical University of Gdańsk, Department of Oncology and Radiotherapy, Medical University of Gdańsk
ShaoZhimingChinaFudan University Cancer Hospital/Department of Breast Surgery
SingerChristianAustriaMedical University of Vienna, Medical University/Center for Breast Health
TanjaSloveniaEuropa Donna
ThuerlimannBeatSwitzerlandSwiss Breast Care Zürich
ToiMasakazuJapanKyoto University Hospital
TolaneySaraUSAHarvard Medcial School / Dana-Farber Cancer Institute, Dana-Farber Cancer Institute
TurnerNicholasUKRoyal Marsden Hospital, Icr
TuttAndrewUKThe Institute of Cancer Research / Breast Cancer Research
van KruchtenMichelNetherlandsUniversity Medical Center of Groningen
VialeGiuseppeItalyEuropean Institute of Oncology Milan
Vrancken PeetersMarie-JeanneNetherlandsnetherlands cancer institute – antoni van leeuwenhoek, Netherlands Cancer Institute – Antoni Van Leeuwenhoek
WatanabeToruJapanHamamatsu Oncology Center
WeberWalterSwitzerlandUniversity Hospital Basel
WildiersHansBelgiumUniversity Hospitals Leuven
XuBingheChinaCancer Hospital, Chinese Academy of Medical Sciences/

subject to changes





We have received and reviewed all submitted abstracts over the course of the past couple of months and we could not be more delighted about all the contributions! 


accepted abstract

The list of all accepted abstracts can be found here.

During the conference all accepted submissions can be viewed as e-posters in the e-poster area and via the congress app. 


book of abstracts

All accepted abstracts have been published in an electronic supplement issue to the journal “The Breast” by Elsevier Publishers. Click here to access the journal. 


best poster awards 2023

A renowned reviewing team honours the three best poster abstracts with the St.Gallen Oncology Conferences Best Poster Award 2023. The awards were presented at the SGBCC 2023 on Wednesday, 15 March 2023.



SGBCC Academy

The St.Gallen-Vienna Breast Cancer Care Educationals for Professionals around the world


The SGBCC 2023 was a great success, bringing together leading experts in the field of breast cancer from around the world to share the latest research, best practices, and insights. The conference featured a range of engaging sessions, including keynote lectures, panel discussions, and interactive workshops, covering a broad range of topics related to breast cancer.

One of the highlights of the conference was the SGBCC Academy, which offered a series of lectures on the most important topics in early breast cancer care, delivered by the panelists of the St. Gallen Consensus. Attendees had the opportunity to access these lectures via the virtual conference platform and participate in daily SGBCC Academy sessions, where they could ask follow-up questions and engage in further discussions on the most pressing issues in patient care.

Looking ahead, we are excited to continue providing exceptional educational opportunities to our attendees. We invite you to mark your calendars for the next St. Gallen International Breast Cancer Conference, which will take place in Vienna from 12 – 15 March 2025. Stay tuned for updates and announcements about the program and speakers, and we look forward to seeing you there.



award winners


St.Gallen International Breast Cancer Award Winner 2023

The Foundation Council of “St.Gallen Oncology Conferences“ (SONK) honors Professor Giuseppe Viale for his extraordinary contribution in research and practice development in the treatment of individuals with breast cancer with the “St.Gallen International Breast Cancer Award 2023“, which was presented during the SGBCC 2023 on 15 March 2023.

Prof. Giuseppe Viale
European Institute of Oncology IRCCS, Milan / Italy

St.Gallen Oncology Conferences (SONK) is privileged to count on Prof. Giuseppe Viale as an active contributor and supporter of the St.Gallen International Breast Cancer Conference and Consensus Guidelines. He is the first pathologist to receive this Award. He added his scientific and professional perspective to provide truly interdisciplinary discussions for the benefit of the best treatment of individuals with early breast cancer. With the St.Gallen Breast Cancer Award 2023, the Foundation St.Gallen Oncology Conferences (SONK) wishes to honour Giuseppe Viale for his extraordinary contributions to breast cancer science.

Find out more about Prof. Giuseppe Viale.

ESO Umberto Veronesi Memorial Award Winner 2023

The European School of Oncology (ESO) honors Professor Benjamin Anderson with the “ESO Umberto Veronesi Memorial Award 2023“, which was presented  during the SGBCC 2023 on 15 March 2023.

Prof. Benjamin Anderson
World Health Organization (WHO), Geneva / Switzerland

Ben Anderson, faculty portrait at the Fred Hutchinson Cancer Research Center, May 24, 2019, in Seattle, Washington. 

Find out more about Prof. Benjamin Anderson


Former St.Gallen International Breast Cancer Award Winners


2021:  Prof. Philip Poortmans, Wilrijk-Antwerp/BE

2019:  Prof. Monica Morrow, New York/USA

2017:  Prof. Martine Piccart-Gebhart, Brussels/BE

2015:  Prof. Alan Coates, Cennential Park/AUS

2013:  Prof. Aron Goldhirsch, Lugano/CH + Milano/IT

2011:  Prof. V. Craig Jordan, Washington, DC/USA

2009:  Prof. Richard Gelber, Boston, MA/USA

2007:  Prof. Michael Baum, London/UK

2005:  Prof. Umberto Veronesi, Milano/IT

2003:  Dr. Gianni Bonadonna, Milano/IT and Dr. Bernard Fisher, Pittsburg, PA/USA










Certificate of attendance / CME credit points


The conference counts for 20 CME credit points from the ACOE and UEMS and is also recognised by the international equivalents. 

In order to obtain your certificate of attendance, SONK requires feedback on its educational and organisational activities. Following the conference, we kindly ask all SGBCC 2023 participants to complete an online evaluation which was sent to you by e-mail after the conference. The certificate of attendance will be sent to you after completion of the online evaluation. 


We are pleased to announce that the webcasts of the St. Gallen International Breast Cancer Conference 2023 will be exclusively available to participants for the next 6 months, providing you with the opportunity to review and revisit the sessions that matter most to you. After this period, the webcasts will be made publicly accessible for everyone to benefit from.

Click here to view the webcasts of the SGBCC 2023.

The password to access the webcasts have been sent to all participants by e-mail.

We hope that these recordings will help you further enhance your knowledge and understanding of the latest developments in the field of breast cancer. Thank you for being a part of SGBCC 2023!


Click on the links below to view the webcasts of the St.Gallen International Breast Cancer Conferences of the previous years:

We thank our sponsors and partners who support the 18th St.Gallen International Breast Cancer Conference 2023.

co-operating partners

promotional partners

As of today, the industry support of SGBCC 2023 is EUR 1,001,090.00.

satellite symposia programme


Wednesday, 15 March 2023
11.30 – 12.30 (CET)Exact Sciences
Thursday, 16 March 2023 
08.00 – 08.45 (CET)Industry sponsored symposium organized by Medscape Oncology Global
11.30 – 12.30 (CET)Novartis Oncology
Friday, 17 March 2023 
11.30 – 12.30 (CET)Daiichi Sankyo Europe GmbH
17.45 – 18.45 (CET)Astra Zeneca



Wednesday, 15 March 2023 | 11:30-12:30

Improve patient care with genomic testing to tailor adjuvant systemic treatment in early HR+, HER2- breast cancer

  • Welcome + opening remarks – Valentina Guarneri (Italy)
  • Genomic testing – where do we stand in terms of clinical evidence? Valentina Guarneri (Italy)
  • Identifying patients for Oncotype DX® testing in my clinical practice – Christos Markopoulos (Greece)
  • Patient’s awareness and understanding of genomic testingRichard Simcock (UK)
  • Panel discussion and Q+A

back to top


Thursday, 16 March 2023 | 08:00-08:45 CET 

Industry session organized by Medscape Oncology Global
Supported by an independent educational grant from Lilly

Conceptualizing Guidelines to Manage Patients with Hormone Receptor–Positive, HER2-Negative Early Breast Cancer

  • Welcome and Introductions – Sara Tolaney (United States)
  • Understanding Hormone Receptor-Positive, HER2-Negative Early Breast Cancer Treatment Guidelines – Giuseppe Curigliano (Italy), Sara M. Tolaney (United States)
  • What If: A Case Review Exploring Clinical Decision-Making and Patient Management – Giuseppe Curigliano (Italy), Sara M. Tolaney (United States)
  • Managing Adjuvant Therapy – Giuseppe Curigliano (Italy), Sara M. Tolaney (United States)
  • Q&A – Giuseppe Curigliano (Italy), Sara M. Tolaney (United States)

back to top


Thursday 16 March 11:30-12:30 CET

The Rise of CDK4/6 Inhibitors in HR+/HER2− Early Breast Cancer: Impact For Patients       
Chair: Peter A. Fasching (Germany)

Faculty: Eva Ciruelos (Spain)

  • Welcome and Introduction – Peter A. Fasching (Germany)
  • Unmet need and CDK4/6 inhibitors in HR+/HER2− early breast cancer – Eva Ciruelos (Spain)
  • QOL and treatment adherence in the adjuvant setting – Peter A. Fasching (Germany)
  • Closing and Key Takeaways – Peter A. Fasching (Germany)
  • Live Q&A – All

back to top


Friday, 17 March 2023, 11:30-12:30 CET

Advances in HER2-expressing breast cancer treatment with antibody-drug conjugates (ADCs): From metastatic to early disease

Chair: Giuseppe Curigliano (Italy)


  • Welcome and introduction – Giuseppe Curigliano (Italy)
  • How next-generation ADCs impact outcomes in HER2-expressing metastatic breast cancer – Barbara Pistilli (France)
  • Translating clinical experience with ADCs from HER2-positive metastatic breast cancer into the early disease setting – Javier Cortés (Spain)
  • Expanding the use of ADCs in HER2-low early breast cancer: What are the key considerations? – Nadia Harbeck (Germany)
  • Panel discussion – All faculty
  • Wrap up and close – Giuseppe Curigliano (Italy)

back to top


Friday, 17th March 2023; 17:45–18:45 CET

Solving the puzzle: Tailoring treatment options in early breast cancer


  • Welcome and introductions – Nadia Harbeck (Germany)
  • Building on the biology: What has changed in the understanding of early breast cancer? – Nadia Harbeck (Germany)
  • Sequencing in the spotlight: Making sense of new treatment options – Andrew Tutt
  • Completing the picture: Multidisciplinary insights for the treatment of patients with eBC – Peter Dubsky, Carlos Barrios
  • Panel discussion – All faculty
  • Meeting close – Nadia Harbeck (Germany)

back to top



St. Gallen Oncology Conferences (SONK)
Rorschacherstrasse 150
9006 St.Gallen / Switzerland
+41 71 243 09 90



Stay tuned and register now for the newsletter of the St.Gallen International Breast Conference 2023 or join us on social media! 

facebook linkedin twitter

Newsletter abonnieren